Hyphens Pharma International Limited on Apr, 21 2026 released a set of responses to substantial and relevant questions submitted by shareholders on its Annual Report for the financial year ended Dec, 31 2025, ahead of the company’s Annual General Meeting scheduled for Apr, 28 2026 in Singapore.

The board said it continues to evaluate a potential transfer of the group’s listing from the Catalist board to the SGX Mainboard, subject to meeting regulatory requirements and market conditions.

Management reported no material financial impact from the Strait of Hormuz closure, although freight costs and lead times have risen. The group is monitoring geopolitical and inflationary risks.

Dermatology treatment Wynzora and antiviral medicine Amenalief remain under regulatory review in selected markets; sales will commence once approvals are granted.

Addressing profitability, the company stated that near-term earnings may fluctuate due to ongoing investments in product portfolio expansion, market development and exchange-rate movements, but reiterated its objective of delivering sustainable earnings growth supported by higher-margin proprietary brands, geographic expansion and operational efficiency.

Employee turnover of about 25% reflects expansion and organisational changes, with no material disruption reported. The board’s annual competency review concludes it has the requisite skills, and it will continue to strengthen capabilities as the business scales.

Nabota, introduced to Singapore and Malaysia in 2023, is showing encouraging early sales, though current revenue contribution is modest.

Inventory controls have been tightened through enhanced demand planning and coordination with partners to mitigate future write-downs.

In Vietnam, softer sales were linked to stricter enforcement of Good Pharmacy Practice requirements and tighter distribution controls, while declines in the “Others” category stemmed from a deliberate move away from lower-margin products.

For its Digital Platform and e-Pharmacy business, primary investment is largely completed; the focus now is on extracting value, improving efficiency and deploying selective artificial-intelligence tools such as the e-MSL module. Continued investment will depend on meeting strategic and financial objectives.

Cargo insurance generally covers the group’s shipments, and current operations avoid active war zones, limiting direct exposure to conflict-related risks.

The company’s sponsor, SAC Capital Private Limited, has reviewed the announcement; the Singapore Exchange has not.